Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study
Open Access
- 20 August 2018
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 149 (1) , 126-138
Abstract
α‐Synuclein is the major component of Lewy bodies and a candidate biomarker for neurodegenerative diseases in which Lewy bodies are common, including Parkinson's disease and dementia with Lewy bodies. A large body of literature suggests that these disorders are characterized by reduced concentrations of α‐synuclein in cerebrospinal fluid (CSF), with overlapping concentrations compared to healthy controls and variability across studies. Several reasons can account for this variability, including technical ones, such as inter‐assay and inter‐laboratory variation (reproducibility). We compared four immunochemical methods for the quantification of α‐synuclein concentration in 50 unique CSF samples. All methods were designed to capture most of the existing α‐synuclein forms in CSF (‘total’ α‐synuclein). Each of the four methods showed high analytical precision, excellent correlation between laboratories (R2 0.83–0.99), and good correlation with each other (R2 0.64–0.93), although the slopes of the regression lines were different between the four immunoassays. The use of common reference CSF samples decreased the differences in α‐synuclein concentration between detection methods and technologies. Pilot data on an immunoprecipitation mass spectrometry (IP‐MS) method is also presented. Our results suggest that the four immunochemical methods and the IP‐MS method measure similar forms of α‐synuclein and that a common reference material would allow harmonization of results between immunoassays. imageKeywords
Funding Information
- Michael J Fox Foundation
This publication has 30 references indexed in Scilit:
- Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with SynucleinopathyPLOS ONE, 2013
- Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian DisordersArchives of Neurology, 2012
- What is a Certified Reference Material?Biomarkers in Medicine, 2012
- Characterization of Semisynthetic and Naturally Nα-Acetylated α-Synuclein in Vitro and in Intact CellsJournal of Biological Chemistry, 2012
- Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 2012
- α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort studyThe Lancet Neurology, 2011
- Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson diseaseNeurology, 2010
- Quantification of α-Synuclein in Cerebrospinal Fluid As a Biomarker Candidate: Review of the Literature and Considerations for Future StudiesBiomarkers in Medicine, 2010
- DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s diseaseBrain, 2010
- Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?Neuroscience Letters, 2009